Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T cells

{
  "id": "MLC-T-ONC-011535",
  "term": "Autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv), derived from the CD19-specific murine immunoglobulin (Ig) G1 monoclonal antibody FMC63, fused to the signaling domain of CD28, the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR+ EGFRt + CD4+ and CD8+ T cells are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response.",
  "synonyms": [
    "autologous anti-CD19CAR-CD28-CD3zeta-EGFRt-expressing CD4+/CD8+ T lymphocytes"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-cd19-car-plus-egfrt-plus-cd4-plus-and-cd8-plus-t-cells/"
}